Left Atrial Appendage Closure with a New Occluder Device : Efficacy, Safety and Mid-Term Performance
Llagostera-Martín, Marc (Hospital del Mar (Barcelona, Catalunya))
Cubero-Gallego, Hector (Hospital del Mar (Barcelona, Catalunya))
Mas-Stachurska, Aleksandra (Institut Hospital del Mar d'Investigacions Mèdiques)
Salvatella, Neus (Hospital del Mar (Barcelona, Catalunya))
Sánchez-Carpintero, Andrea (Hospital del Mar (Barcelona, Catalunya))
Tizón-Marcos, Helena (Institut Hospital del Mar d'Investigacions Mèdiques)
García-Guimaraes, Marcos (Hospital del Mar (Barcelona, Catalunya))
Calvo-Fernández, Alicia (Hospital del Mar (Barcelona, Catalunya))
Molina, Luis (Universitat Autònoma de Barcelona. Departament de Medicina)
Vaquerizo, Beatriz (Universitat Autònoma de Barcelona. Departament de Medicina)

Fecha:	2021
Resumen:	The LAmbre TM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbre TM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9. 4 years), with a high proportion of comorbidities. The mean CHADS-VASc and HAS-BLED scores were 4. 6 ± 1. 6 and 3. 9 ± 1. 0, respectively. Previous history of a major bleeding event was present in 37 patients (67. 3%). Procedural success was achieved in 54 patients (98. 2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1. 8%) and pericardial tamponade in two patients (3. 6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1. 8%), transient ischemic attack/ischemic stroke (1. 8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbre TM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Left atrial appendage closure ; Atrial fibrillation ; Stroke ; LAmbre
Publicado en:	Journal of clinical medicine, Vol. 10 (april 2021) , ISSN 2077-0383

DOI: 10.3390/jcm10071421
PMID: 33915971

11 p, 10.2 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados